Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 12NIH 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Breast Neoplasms 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 238Biopsy 196Nivolumab 57Cyclophosphamide 52X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 32Gemcitabine 32atezolizumab 31CTLA-4 Antigen 31olaparib 28fludarabine 27venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × talazoparib × 90 days × Clear all
NCT04334941 2026-06-05

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

National Cancer Institute (NCI)

Phase 2 Active not recruiting
103 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05327010 2026-05-13

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
88 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡